Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting.

[1]  R. Shannon,et al.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. , 2006, Journal of cardiac failure.

[2]  J. Holst,et al.  The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. , 2006, American journal of physiology. Endocrinology and metabolism.

[3]  R. Shannon,et al.  Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. , 2005, American journal of physiology. Heart and circulatory physiology.

[4]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[5]  B. Troost,et al.  Attempted control of hyperglycemia during cardiopulmonary bypass fails to improve neurologic or neurobehavioral outcomes in patients without diabetes mellitus undergoing coronary artery bypass grafting. , 2005, The Journal of thoracic and cardiovascular surgery.

[6]  Jun Zhu,et al.  Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. , 2005, JAMA.

[7]  R. Shannon,et al.  Glucagon-Like Peptide-1 Limits Myocardial Stunning following Brief Coronary Occlusion and Reperfusion in Conscious Canines , 2005, Journal of Pharmacology and Experimental Therapeutics.

[8]  R. Shannon,et al.  Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy , 2004, Circulation.

[9]  D. Hett,et al.  A prospective randomized study to evaluate stress response during beating-heart and conventional coronary revascularization. , 2004, The Annals of thoracic surgery.

[10]  R. Shannon,et al.  Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion , 2004, Circulation.

[11]  F. McAlister,et al.  Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes. , 2003, Diabetes care.

[12]  G. Grunkemeier,et al.  Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. , 2003, The Journal of thoracic and cardiovascular surgery.

[13]  James A. Young,et al.  Outcomes and perioperative hyperglycemia in patients with or without diabetes mellitus undergoing coronary artery bypass grafting. , 2003, The Annals of thoracic surgery.

[14]  M. Demircin,et al.  Perioperative hyperglycemia is a strong correlate of postoperative infection in type II diabetic patients after coronary artery bypass grafting. , 2002, Endocrine journal.

[15]  D. McGiffin,et al.  Glucose-insulin-potassium infusion for myocardial protection during off-pump coronary artery surgery. , 2002, The Annals of thoracic surgery.

[16]  M Schetz,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[17]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[18]  K. Malmberg.  Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.

[19]  Kenichi A. Tanaka,et al.  The inflammatory response to cardiopulmonary bypass , 1997 .

[20]  R. Shemin,et al.  Glucose-insulin-potassium solutions enhance recovery after urgent coronary artery bypass grafting. , 1997, The Journal of thoracic and cardiovascular surgery.

[21]  K. Minaker,et al.  The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects , 1994, Regulatory Peptides.

[22]  Liu Xinbing,et al.  Intensive insulin therapy for the critically ill patients with stress hyperglycemia , 2008 .